Otsuka Pharmaceutical Development & Commercialization, Inc.

8 marketed · 27 in Phase 3

Quick facts

Marketed products

Abilify MyCite® · Psychiatry
Abilify MyCite is an ingestible tablet formulation of aripiprazole, a dopamine D2 and serotonin 5-HT1A receptor partial agonist, equipped with an ingestible sensor that tracks medication adherence.
Aripiprazole or other oral antipsychotics · Psychiatry
Aripiprazole is a partial agonist at dopamine D2 and serotonin 5-HT1A receptors that modulates dopaminergic and serotonergic neurotransmission to treat psychotic and mood disorders.
Lamotrigine + Aripiprazole · Psychiatry/Neurology
Lamotrigine stabilizes neuronal membranes by blocking sodium channels, while aripiprazole acts as a dopamine D2/D3 receptor partial agonist, together modulating neurotransmission to treat mood and psychotic disorders.
Lithium or Valproate with Aripiprazole · Psychiatry
Aripiprazole acts as a dopamine D2/D3 receptor partial agonist and serotonin 5-HT1A partial agonist, while lithium and valproate modulate intracellular signaling and gene expression to enhance mood stabilization and reduce manic/depressive symptoms.
OBR · Psychiatry / Neurology
OBR is a long-acting injectable antipsychotic that blocks dopamine D2 receptors in the brain to treat schizophrenia and bipolar disorder.
Paroxetine CR · Psychiatry / Neurology
Paroxetine CR selectively inhibits the reuptake of serotonin at the neuronal synapse, increasing serotonin availability in the brain.
Quetiapine or Risperidone + Aripiprazole · Psychiatry
These atypical antipsychotics block dopamine and serotonin receptors in the brain to reduce psychotic symptoms and stabilize mood.
Stimulant Therapy

Phase 3 pipeline

Aripiprazole+ ADT · Psychiatry / Oncology
Aripiprazole is a dopamine D2/D3 receptor partial agonist combined with an androgen deprivation therapy (ADT) agent to treat psychiatric symptoms in patients undergoing hormone therapy.
Aripiprazole (BMS-337039) · Psychiatry
Aripiprazole is a partial agonist at dopamine D2 and serotonin 5-HT1A receptors that modulates dopaminergic and serotonergic neurotransmission in the brain.
Aripiprazole depot 25 or 50 mg
Aripiprazole IM Depot
AVP-786-18 · Neurology
AVP-786 is a combination of deuterated dextromethorphan and quinidine that enhances sigma-1 receptor signaling to reduce neurological symptoms.
AVP-786-28 · Neurology
AVP-786 is a combination of deuterated dextromethorphan and quinidine that enhances sigma-1 receptor signaling to reduce agitation and behavioral symptoms in neurodegenerative diseases.
AVP-786-42.63 · Neurology
AVP-786 is a combination of deuterated dextromethorphan and quinidine that enhances sigma-1 receptor signaling to reduce neuroinflammation and neurodegeneration.
BPaL · Infectious Disease
BPaL is a three-drug combination regimen (bedaquiline, pretomanid, and linezolid) that inhibits mycobacterial ATP synthase and protein synthesis to kill drug-resistant tuberculosis bacteria.
BPaQ
BPaQ is a prodrug formulation designed to improve the oral bioavailability and therapeutic delivery of its active moiety.
BPaQM · Infectious Disease
BPaQM is a novel antimalarial compound that acts as a blood schizonticide to prevent malaria parasite multiplication in red blood cells.
Brexpiprazole +ADT · Psychiatry / Mental Health
Brexpiprazole is an atypical antipsychotic that acts as a dopamine D2 receptor partial agonist and serotonin 5-HT1A receptor partial agonist, combined with adjunctive antidepressant therapy (ADT) to treat major depressive disorder.
Brexpiprazole (OPC-34712) · Psychiatry/Neurology
Brexpiprazole is a serotonin-dopamine activity modulator (SDAM) that acts as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors while antagonizing serotonin 5-HT2A receptors.
Centanafadine SR · Psychiatry / Neurology
Centanafadine is a triple monoamine reuptake inhibitor that blocks the reuptake of serotonin, norepinephrine, and dopamine.
Delamanid + OBR · Infectious Disease
Delamanid inhibits mycobacterial cell wall synthesis by targeting mycolic acid production, while OBR (optimized background regimen) provides synergistic anti-tuberculous activity through multiple complementary mechanisms.
JNT-517 Tablet · Obesity / Metabolic Disease
JNT-517 is a selective serotonin 5-HT2C receptor agonist that promotes weight loss by increasing satiety and reducing appetite.
Olanzapine or Quetiapine or Risperidone · Psychiatry
These atypical antipsychotics block dopamine D2 and serotonin 5-HT2A receptors to reduce psychotic symptoms and stabilize mood.
OPA-15406 · Dermatology / Immunology
OPA-15406 is a selective JAK1 inhibitor that reduces inflammatory signaling to treat immune-mediated skin diseases.
OPC-34712 · Psychiatry/Neurology
OPC-34712 is a selective serotonin 5-HT7 receptor antagonist that modulates serotonergic neurotransmission to treat psychiatric and neurological disorders.
OPC-34712 + ADT · Oncology
OPC-34712 is a selective serotonin 5-HT7 receptor antagonist combined with androgen deprivation therapy (ADT) to treat prostate cancer.
OPC-34712 [Brexpiprazole] High Dose · Psychiatry
Brexpiprazole is a partial agonist at serotonin 5-HT1A receptors and a partial agonist at dopamine D2 receptors.
OPC-6535 Tablets (drug) · Immunology
OPC-6535 is a selective antagonist of the P2X7 receptor, an ATP-gated ion channel involved in inflammatory and immune responses.
Placebo + ADT · Oncology
Androgen deprivation therapy (ADT) involves the use of medications to suppress the production of androgens, such as testosterone, which can fuel the growth of prostate cancer cells.
Placebo depot
Placebo depot does not have an active pharmacological mechanism; it is used as a control in clinical trials.
Placebo + OBR
This is a placebo control arm combined with OBR (a comparator treatment), used in a Phase 3 clinical trial to establish efficacy and safety baselines.
Placebo Tablet: BID
Placebo has no active pharmacological mechanism; it is an inert substance used as a control in clinical trials.
SEP-363856 · Psychiatry
SEP-363856 is a trace amine-associated receptor 1 (TAAR1) agonist that modulates glutamatergic and dopaminergic neurotransmission in the brain.
SEP363856 · Psychiatry
SEP363856 is a trace amine-associated receptor 1 (TAAR1) agonist that modulates glutamatergic and dopaminergic neurotransmission in the brain.

Phase 2 pipeline

Phase 1 pipeline

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: